drugset / Trial / NCT00625196

Comparing Two Respiratory Drugs in Combination and Separately From a Novel Inhaler Device in Healthy Japanese Subjects

NCT00625196

Phase 1 Completed 16 enrolled GlaxoSmithKline
RandomizedCrossoverTreatment

Summary

A combination of the corticosteroid GW685698X and the long-acting ß2-agonist GW642444M is being developed for once daily administration for the maintenance treatment of asthma and COPD. GW642444M and GW685698X will be simultaneously co-administered from a single device and compared with GW642444M and GW685698X administered separately in order to determine whether co-administration affects the safety, tolerability, pharmacodynamic and/or pharmacokinetics of either compound in healthy Japanese subjects.

Timeline

Start
2008-02-27
Primary completion
2008-05-06
Completion
2008-05-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone foroate Unknown 800 ug Inhaled
Subject Vilanterol Other / unclassified 50 ug Inhaled

Indications